Bosse U - Search Results

1

Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content.

Brandt B, Vogt U, Harms F, Bosse U, Zänker KS, Assmann G. Brandt B, et al. Among authors: bosse u. Gene. 1995 Jun 14;159(1):29-34. doi: 10.1016/0378-1119(94)00651-8. Gene. 1995. PMID: 7607569

2

Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis.

Brandt B, Vogt U, Schlotter CM, Jackisch C, Werkmeister R, Thomas M, von Eiff M, Bosse U, Assmann G, Zänker KS. Brandt B, et al. Among authors: bosse u. Gene. 1995 Jun 14;159(1):35-42. doi: 10.1016/0378-1119(94)00652-9. Gene. 1995. PMID: 7607571

3

Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer.

Vogt U, Bielawski K, Schlotter CM, Bosse U, Falkiewicz B, Podhajska AJ. Vogt U, et al. Among authors: bosse u. Gene. 1998 Nov 26;223(1-2):375-80. doi: 10.1016/s0378-1119(98)00454-5. Gene. 1998. PMID: 9858771

4

c-myc oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer.

Falkiewicz B, Schlotter CM, Bosse U, Bielawski K, Vogt U. Falkiewicz B, et al. Among authors: bosse u. Acta Biochim Pol. 2000;47(1):149-56. Acta Biochim Pol. 2000. PMID: 10961688

5

Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.

Vogt U, Falkiewicz B, Bielawski K, Bosse U, Schlotter CM. Vogt U, et al. Among authors: bosse u. Acta Biochim Pol. 2000;47(1):157-64. Acta Biochim Pol. 2000. PMID: 10961689

6

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.

Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. Schlotter CM, et al. Among authors: bosse u. Breast Cancer Res. 2003;5(2):R30-6. doi: 10.1186/bcr568. Epub 2003 Jan 13. Breast Cancer Res. 2003. PMID: 12631396 Free PMC article.

7

[Impact of DNA image cytometry (ICM) parameter and established prognostic factors on disease free survival (DFS) and overall survival (OS) of node-negative breast cancer (NNBC) patients].

Schlotter CM, Vogt U, Bosse U, Wassmann K. Schlotter CM, et al. Among authors: bosse u. Zentralbl Gynakol. 2003 Sep;125(9):368-74. doi: 10.1055/s-2003-43040. Zentralbl Gynakol. 2003. PMID: 14569519 German.

8

[Clinical importance of histology, grading and ploidies in primary breast cancer].

Schlotter CM, Kropp S, Wichert S, Vogt U, Krieg V, Bosse U, Wassmann K. Schlotter CM, et al. Among authors: bosse u. Zentralbl Gynakol. 1999;121(8):384-8. Zentralbl Gynakol. 1999. PMID: 10486881 German.

9

Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay.

Vogt U, Striehn E, Bosse U, Klinke F, Falkiewicz B. Vogt U, et al. Among authors: bosse u. Acta Biochim Pol. 1999;46(2):299-302. Acta Biochim Pol. 1999. PMID: 10547031

10

Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.

Vogt U, Bielawski KP, Bosse U, Schlotter CM. Vogt U, et al. Among authors: bosse u. Oncol Rep. 2004 Nov;12(5):1109-14. Oncol Rep. 2004. PMID: 15492801

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters